Key Highlights
- Neuren Pharmaceuticals (ASX:NEU) lifted its expected 2026 trofinetide income to USD 91 million to USD 93 million.
- Third-quarter Royalty income was USD 16.4 million, up 51% from a year earlier.
- The first commercial sale in Europe generated a USD 35 million milestone for Neuren.
- Licensee Acadia Pharmaceuticals raised its global 2026 trofinetide sales guidance to USD 505 million to USD 520 million.
Neuren Pharmaceuticals (ASX:NEU), a developer of treatments for neurological disorders, increased its 2026 income guidance for trofinetide in a 5 November update. The revision followed increased annual sales expectations from its commercial partner and a milestone earned after the October launch in Germany. The company also reported third-quarter royalty income and outlined its partner’s plans for a regulatory submission in Japan.
Third-quarter sales and royalties
Acadia Pharmaceuticals reported USD 140 million in third-quarter 2026 net sales for trofinetide, an increase of 39% year on year and 12% from the second quarter. The sales figure includes the different forms of trofinetide unless otherwise specified. Neuren attributed growth to uptake of the DAYBUE STIX powder among existing patients, new patients beginning treatment and patients restarting treatment.
More than half of US DAYBUE users were taking the powder form by the time of the update, compared with 40% at the end of the second quarter. Neuren earned USD 16.4 million of third-quarter royalty income, up 51% year on year. Acadia holds an exclusive worldwide licence from Neuren to develop and commercialise trofinetide, which is marketed in the United States for Rett syndrome.
German launch and European royalty terms
DAYBU launched in Germany in October, after the third quarter had ended. The first European commercial sale earned Neuren USD 35 million under its licence agreement. Neuren reported that patients were already receiving treatment in Germany when it issued the November announcement. The company included the launch milestone in annual trofinetide income alongside expected royalties.
Under the European terms, Neuren is entitled to a 17% royalty on the first USD 150 million of annual net sales, 20% on the portion above USD 150 million and up to USD 300 million, and 23% on sales above USD 300 million. The agreement also provides for one-time annual sales milestones. The first threshold is USD 120 million of net sales in a calendar year, which would trigger USD 15 million. Further one-time milestones are USD 30 million at USD 240 million of annual sales, USD 50 million at USD 400 million and USD 75 million at USD 600 million.
Patent development and planned Japan filing
Neuren reported that a US Patent covering weight-banded trofinetide dosing was allowed during the third quarter. The company said that the additional protection extended the US patent horizon for DAYBUE and DAYBUE STIX by nearly five years, through March 2041.
Acadia completed a Phase 3 trofinetide study in Japan in patients with Rett syndrome. Neuren said its partner considered the results consistent with the earlier LAVENDER Phase 3 study and supportive of a planned regulatory filing in 2027. Acadia continued to seek a distribution partner while preparing for the submission. A potential 2028 launch remained subject to regulatory approval.
What changed in the 2026 forecast
Neuren now expects annual trofinetide royalties of USD 56 million to USD 58 million, compared with its previous range of USD 53 million to USD 56 million. That revision followed Acadia’s increase in annual global net sales guidance to USD 505 million to USD 520 million from a previous range of USD 480 million to USD 510 million. Including the German launch milestone, Neuren’s November update put expected total trofinetide income at USD 91 million to USD 93 million for 2026.






Please wait processing your request...